EUVIMEDEUVIMED entdecken
Crossref

In Vivo Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1

Jenny A Greig, Camilo Breton, Melanie K Smith, Thomas Furmanak, Peter Bell, Peter Clark, James M Wilson iD

Human Gene Therapy · 2026

DOI: 10.1177/10430342261460681 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Jenny A Greig und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gene Therapy Program, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Hyperoxaluria, Primary, Gene Editing, Alcohol Oxidoreductases, Genetic Therapy. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Precision BioSciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder that leads to kidney and liver failure. PH1 is caused by a mutation in the alanine glyoxylate aminotransferase ( AGXT ) gene, which encodes a key metabolic enzyme that converts glyoxylate to glycine in the liver. Inability to metabolize glyoxylate leads to oxalate overproduction, yielding insoluble calcium oxalate crystals; accumulation of these crystals leads to progressive organ failure. Here, we used a novel, minimally disruptive genome-editing approach to disrupt the mechanism of action of hydroxyacid oxidase 1 (HAO1), an upstream enzyme in the glyoxylate metabolic pathway. Successful gene editing and disruption of the HAO1 gene is expected to increase levels of glycolate, a harmless intermediate of the glycine metabolic pathway, thereby preventing the formation of calcium oxalate crystals. We intravenously administered an adeno-associated virus (AAV) vector expressing the M1HAO1 meganuclease to both wild-type and Agxt −/− mice, a mouse model of PH1. We observed >30% editing of HAO1 in Agxt −/− mice, correlating with a dose-dependent increase in serum glycolate levels. At the highest dose tested, urine glycolate levels increased by 79%, with a concomitant 75% decrease in urine oxalate levels. We also evaluated in vivo targeting in rhesus macaques injected with AAV expressing two different versions of the HAO1 meganuclease. Dose-dependent editing of hepatic DNA and RNA was achieved, and serum glycolate levels changed in a manner consistent with successful liver editing; additionally, the treatment was well tolerated. Our results indicate that AAV-delivered meganucleases can effectively target HAO1 in mice and nonhuman primates to achieve high levels of HAO1 gene editing. Moreover, increased glycolate levels in serum indicate that this intervention significantly impacts the HAO1-mediated glycolate-to-glyoxylate pathway. These data suggest that this approach may represent an effective treatment for PH1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperoxaluria, PrimaryGene EditingAlcohol OxidoreductasesGenetic TherapyAnimalsDependovirusMiceTransaminasesHumansDisease Models, AnimalGenetic VectorsGlycolatesGene Therapy AgentsMice, KnockoutLiver

Stichwörter der Autor:innen

adeno-associated virusgene editinggenome editinghydroxyacid oxidase 1meganucleaseprimary hyperoxaluria type 1

Substanzen

TransaminasesAlcohol OxidoreductasesAlanine-glyoxylate transaminaseGlycolatesHAO1 protein, humanglycolic acid

Autor:innen und Institutionen

  • Gene Therapy Program, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: James M Wilson

Förderung

  • Precision BioSciences

Zitieren

APA

Greig, J. A., Breton, C., Smith, M. K., Furmanak, T., Bell, P., Clark, P., & Wilson, J. M. (2026). In Vivo Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1. Human Gene Therapy. https://doi.org/10.1177/10430342261460681

Vancouver

Greig JA, Breton C, Smith MK, Furmanak T, Bell P, Clark P, et al. In Vivo Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1. Human Gene Therapy. 2026. doi:10.1177/10430342261460681

BibTeX
@article{Greig2026,
  author = {Greig, Jenny A and Breton, Camilo and Smith, Melanie K and Furmanak, Thomas and Bell, Peter and Clark, Peter and Wilson, James M},
  title = {In Vivo Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1},
  journal = {Human Gene Therapy},
  year = {2026},
  doi = {10.1177/10430342261460681}
}
Kostenlos starten →